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Inhibition of Triggered
Activities in Pulmonary Veins
Do Statins Have a Direct and
Clinically Relevant Antiarrhythmic Effect?*
Gan-Xin Yan, MD, PHD†‡§
Zuyi Yuan, MD, PHD†‡
Wynnewood and Philadelphia, Pennsylvania;
and Xi’an, China
Statins, also known as HMG-CoA (3-hydroxy-3-methyl-
glutaryl-coenzyme A) reductase inhibitors, are the world’s
most widely prescribed medications. Approximately 24
million people take statins, with 200 million prescriptions
filled in 2009 in the U.S. alone. Rapidly accumulating basic
and clinical evidence shows that the beneficial effects of
statins on cardiovascular system extend well beyond their
primary lipid-lowering effect in primary and secondary
prevention of coronary heart disease. Among the pleiotropic
effects of statins, the most intriguing is their beneficial effect
in prevention of atrial fibrillation (AF). In the GISSI-HF
(Effect of Rosuvastatin in Patients with Chronic Heart
Failure) trial in which patients were randomly assigned to
treatment of rosuvastatin at 10 mg daily or placebo, rosuv-
See page 986
astatin reduced the incidence of new onset of AF in patients
with stable heart failure after a median follow-up period of
3.7 years (1). The clinical data indicate that the reduced risk
of AF after use of statins for a number of years appears to be
independent of the reduction in serum cholesterol levels (2).
Conversely, statins also reduce the risk of AF in the setting
of acute events, such as after cardiac surgery or noncardiac
thoracic surgery, in which AF occurs within a relatively
short and fixed time window (often in days) (3).
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relationships to disclose.The question is how statins affect electrophysiological
properties of the atria and adjacent tissues such as pulmo-
nary veins that participate in the development of AF. The
pleiotropic properties of statins, which may be beneficial to
health of the atria and pulmonary veins so that the substrate
and the risk factors for the development of AF can be
limited, include their anti-inflammatory effect (4), inhibi-
tion of platelet activation (5), improvement of endothelial
function (6), preventative and reverse atrial remodeling (7),
and reduction of oxidative stress. However, these effects on
the electrical properties of the atria and pulmonary veins are
indirect and undistinguished.
In this issue of the Journal, Sicouri et al. (8) reported their
interesting findings that simvastatin, one of the commonly
prescribed statins, exerts a direct antiarrhythmic effect in the
pulmonary veins by suppressing triggered activities respon-
sible for the development of AF (8). They found that
simvastatin at concentrations of 10 to 20 nM suppressed or
abolished late-phase 3 early afterdepolarizations (EADs)
and delayed afterdepolarizations (DADs), which were elic-
ited by acetylcholine, isoproterenol, high extracellular Ca2,
or their combination, plus rapid pacing, in the endocardial
extension of atrial muscle covering the pulmonary veins. It
is well known that EAD- and DAD-dependent triggered
activities are responsible for a variety of cardiac arrhythmias
(9). Recent clinical evidence and basic research studies have
shown that triggered activities from the pulmonary veins
contribute importantly to the development of AF (10,11).
In the study by Sicouri et al. (8), it is particularly interesting
that simvastatin can abolish the late-phase 3 EADs induced
by acetylcholine plus high extracellular Ca2. Unlikely
EADs observed in the ventricular tissues under condition of
delayed repolarization, the late-phase 3 EADs occur in the
atria or pulmonary veins when action potential duration
becomes markedly shortened (9,12). The late-phase 3 EAD
is thought to be an important source for atrial extrasystoles
capable of initiating AF. This is because the condition
favoring the genesis of the late-phase 3 EADs also shortens
the atrial impulse wavelength, facilitating the formation of a
re-entrant substrate.
The study by Sicouri et al. (8) has significant clinical
implications. First of all, statins such as simvastatin are the
most commonly prescribed medications for primary and
secondary prevention of coronary heart disease, whereas AF
is the most common cardiac arrhythmia that requires
medical attention. In other words, a large population of
people who require the therapy of statins are likely to have
a higher risk for the development of AF. Secondly, if statins
exhibit a direct and clinically relevant antiarrhythmic effect,
statins would have more broad clinical applications. In the
events in which AF often occurs within a few of days, such
as at a perioperative stage or shortly after electrical cardio-
version of AF, direct antiarrhythmic effects of statins would
provide prompt protection in reducing the AF incidence.
This appears supported by clinical evidence (3,13).
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February 22, 2011:994–5 Antiarrhythmic Effect of StatinsThe underlying ionic mechanisms for the effects of
simvastatin on electrical activities of the pulmonary veins are
unknown. In addition to their suppression of EADs and
DADs, simvastatin also caused a significant decrease in
action potential amplitude and marked use-dependent de-
pression of maximum rate of rise of action potential up-
stroke (Vmax) (8). These effects of statins are similar to
those of ranolazine, a compound that inhibits fast and late
sodium currents. Therefore, one would attribute the effects
of simvastatin to the inhibition of the sodium current.
Surprisingly, the data from the study by Sicouri et al. (8)
showed that simvastatin up to 5 M did not produce any
ignificant effects on the fast as well as the late sodium
urrent. The authors explained it and pointed out that the
ffects of simvastatin on Vmax and action potential ampli-
ude were secondary to simvastatin-induced depolarization
nd a more positive take-off potential at the faster rates (8).
owever, that cannot clearly explain why simvastatin in-
ibits both EADs and DADs, because depolarizations to a
ore positive resting membrane potential per se have no
irect inhibitory influence on EADs and DADs. Further
tudies to explore ionic mechanisms of statins are necessary.
As simvastatin is highly bound to the plasma protein, its
ormal unbound concentration in plasma is in the range of
.5 to 1 nM (14). That appears to be lower than the
oncentrations (10 to 20 nM) used in the Sicouri et al. (8)
tudy. One may question whether simvastatin could accu-
ulate in atrial myocytes or pulmonary veins to a concen-
ration range in which clinically relevant electrophysiologi-
al effects can be observed. However, it should be
mphasized that the real human plasma concentration of
imvastatin can fluctuate in a relatively large range and be
ignificantly different in individual patients. In addition,
umerous medications with a property to inhibit CYP450
soenzymes can significantly increase the plasma concentra-
ion of statins. Some of them can result in a 20-fold
ncrease in bioavailability of statins (15). More importantly,
everal commonly used drugs in treatment of AF, including
miodarone, verapamil, and digoxin, also increase the
lasma concentration of statins (15). That probably explains
hy the combination of amiodarone and statins improves
reedom from recurrence of AF after successful cardiover-
ion (13). In future studies, statins should be evaluated in a
ore broad range of concentrations for their direct antiar-
hythmic effects in vitro as well as in vivo models.
Although there is clinical evidence that use of statins is
lso associated with less risk of ventricular arrhythmias (16),
irect antiarrhythmic effect of statins in the ventricles has
ot been reported. Direct inhibition of EADS and DADs
y statins in the pulmonary veins indicates that statins may
otentially exert a similar protective effect in the ventricles,
nd a role of statins through their antiarrhythmic effects in
eduction of all-cause mortality cannot be ruled out. It
ould be, therefore, interesting to test whether statins haveny antiarrhythmic effects in the ventricles. eAs discussed, the finding that statins exert direct antiar-
hythmic effects in an animal model is encouraging and calls
or further basic and clinical research in this field. The
uture studies on statins should focus on their ionic mech-
nisms, dose-response relation, safety in terms of proar-
hythmic potentials, and clinical outcomes in patients prone
o arrhythmias of cardiac arrhythmias. Only after these
nvestigations will we be more confident in applying statins
o our patients for the purpose of antiarrhythmia therapy.
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